AZNAstraZenecaRunning, no new patients
A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations
Non-Small Cell Lung Cancer (NSCLC)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 60 (final count)
- Started
- Jul 18, 2023
- Main results expected
- Oct 1, 2027
- Fully finished
- Oct 1, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with adverse events (AEs)
Measured over: From screening (Day-28) to survival follow up (Approximately 52 months after the first participant is dosed)
Progression Free Survival (PFS)
Measured over: From date of first dose of study intervention until radiological disease progression or death due to any cause (Approximately 52 months after the first participant is dosed)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05801029 · record last updated 2026-09-08 · checked 2026-11-09 15:47 UTC